T
Tomasz Sacha
Researcher at Jagiellonian University
Publications - 127
Citations - 1670
Tomasz Sacha is an academic researcher from Jagiellonian University. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 17, co-authored 107 publications receiving 1231 citations. Previous affiliations of Tomasz Sacha include Jagiellonian University Medical College.
Papers
More filters
Journal ArticleDOI
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Nicholas C.P. Cross,Helen E. White,Dolors Colomer,Hans Ehrencrona,Letizia Foroni,Enrico Gottardi,Thoralf Lange,Thomas Lion,K Machova Polakova,Stéphanie Dulucq,Giovanni Martinelli,E. Oppliger Leibundgut,Niels Pallisgaard,Gisela Barbany,Tomasz Sacha,Rodica Talmaci,Barbara Izzo,Giuseppe Saglio,Fabrizio Pane,Martin C. Müller,Andreas Hochhaus +20 more
TL;DR: Detailed laboratory recommendations are presented to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Journal ArticleDOI
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
Verena S. Hoffmann,Michele Baccarani,Joerg Hasford,Doris Lindoerfer,Sonja Burgstaller,Dubravka Sertić,Paul Costeas,Jiří Mayer,Karel Indrak,Hele Everaus,Perttu Koskenvesa,Joelle Guilhot,Gabriele Schubert-Fritschle,Fausto Castagnetti,F. Di Raimondo,Sandra Lejniece,Laimonas Griskevicius,Noortje Thielen,Tomasz Sacha,Andrzej Hellmann,Anna G. Turkina,Andrey Zaritskey,Andrija Bogdanovic,Zuzana Sninská,Irena Preloznik Zupan,J-L Steegmann,Bengt Simonsson,Richard E. Clark,A. Covelli,G. Guidi,Ruediger Hehlmann +30 more
TL;DR: The proportion of Sokal and Euro score high-risk patients seen in many countries indicates that trial patients were not a positive selection, and from a clinical point of view the results of most trials can be generalized to most countries.
Journal ArticleDOI
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
François Xavier Mahon,Carla Boquimpani,Dong-Wook Kim,Noam Benyamini,Nelma Cristina D. Clementino,Vasily Shuvaev,Sikander Ailawadhi,Jeffrey H. Lipton,Anna G. Turkina,Raquel De Paz,Beatriz Moiraghi,Franck E. Nicolini,Jolanta Dengler,Tomasz Sacha,Naoto Takahashi,Rafik Fellague-Chebra,Sandip Acharya,Stephane Wong,Yu Jin,Timothy P. Hughes +19 more
TL;DR: In this article, the authors evaluated treatment-free remission after discontinuation of second-line nilotinib therapy in chronic myeloid leukemia (CML) using a single-group, phase 2, open-label study.
Journal ArticleDOI
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
Verena S. Hoffmann,Michele Baccarani,Joerg Hasford,Fausto Castagnetti,F. Di Raimondo,L.F. Casado,Anna G. Turkina,Daniela Zackova,Gert J. Ossenkoppele,Andrey Zaritskey,Martin Höglund,Bengt Simonsson,Karel Indrak,Zuzana Sninská,Tomasz Sacha,Richard E. Clark,Andrija Bogdanovic,Andrzej Hellmann,Laimonas Griskevicius,Gabriele Schubert-Fritschle,Dubravka Sertić,Joelle Guilhot,Sandra Lejniece,Irena Preloznik Zupan,Sonja Burgstaller,Perttu Koskenvesa,Hele Everaus,Paul Costeas,Doris Lindoerfer,Gianantonio Rosti,Susanne Saussele,Andreas Hochhaus,Ruediger Hehlmann +32 more
TL;DR: The new EUTOS long-term survival score was validated: the OS of patients differed significantly between the three risk groups, and the current management of patients with tyrosine kinase inhibitors resulted in responses and outcomes in the range reported from clinical trials.
Journal Article
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Francois-Xavier Mahon,Carla Boquimpani,Dong-Wook Kim,Noam Benyamini,Nelma Cristina D. Clementino,Vasily Shuvaev,Sikander Ailawadhi,Jeffrey H. Lipton,Anna G. Turkina,Raquel De Paz,Beatriz Moiraghi,Franck E. Nicolini,Jolanta Dengler,Tomasz Sacha,Naoto Takahashi,Rafik Fellague-Chebra,Sandip Acharya,Stephane Wong,Yu Jin,Timothy P. Hughes +19 more
TL;DR: The ENESTcmr (Evaluating Nilotinib Efficacy and Safety in Clinical TrialsComplete Molecular Response) study demonstrated that switching to nilotinib may provide a path to achieving DMR, confirming the feasibility of TFR after sustained DMR in patients receiving TKIs.